Palisade Bio (NASDAQ:PALI) completed patient enrollment in its dose optimization study of LB1148, a broad-spectrum serine protease inhibitor that acts to neutralize digestive enzymes, potentially reducing intestinal damage.
In a statement, J.D. Finley, CEO of Palisade, said the company remains on track for the Phase 2 topline data readout for the prevention of post-surgical abdominal adhesions in the coming weeks. “The data from these two studies will provide meaningful information related to our future clinical development of LB1148,” he added.
The dose optimization study was designed to generate valuable pharmacokinetic and pharmacodynamic data across multiple doses in healthy adult volunteers and to determine if a different dosing protocol might enhance the risk profile while simultaneously providing efficacy for the development program moving forward.
